Servizio Comunitario di Informazione in materia di Ricerca e Sviluppo - CORDIS

Le informazioni sui progetti di Orizzonte 2020 e ora anche le relative sintesi delle relazioni sono disponibili su CORDIS. Tutti i progetti H2020 possono essere scaricati dal Portale Open Data dell'UE .

My refinements


Download results of this page


Perfeziona per:

Tipo di contenuto

Progetto (661)
Risultato in breve (6)
Sintesi della relazione (304)

Paese

Albania (2)
Argentina (2)
Australia (16)
Austria (78)
Bangladesh (1)
Belgio (146)
Benin (1)
Brasile (4)
Bulgaria (8)
Burkina Faso (1)
Cambogia (1)
Canada (16)
Cina (2)
Cipro (11)
Colombia (2)
Corea del Sud (6)
Costa d’Avorio (1)
Croazia (14)
Cuba (2)
Danimarca (110)
Ecuador (1)
Estonia (17)
Ex Repubblica iugoslava di Macedonia (3)
Finlandia (75)
Francia (227)
Gabon (1)
Germania (307)
Ghana (1)
Giamaica (1)
Giappone (1)
Grecia (76)
India (1)
Irlanda (57)
Islanda (11)
Israele (50)
Italia (239)
Kirghizistan (1)
Kosovo (2)
Lettonia (12)
Lituania (2)
Lussemburgo (15)
Malawi (2)
Malta (2)
Messico (2)
Mozambico (2)
Nepal (2)
Norvegia (47)
Nuova Caledonia (1)
Paesi Bassi (256)
Pakistan (2)
Polinesia francese (1)
Polonia (46)
Portogallo (62)
Regno Unito (340)
Repubblica ceca (31)
Romania (20)
Senegal (4)
Serbia (11)
Slovacchia (11)
Slovenia (29)
Spagna (261)
Sri Lanka (1)
Stati Uniti (49)
Sud Africa (5)
Svezia (141)
Svizzera (92)
Tagikistan (1)
Taiwan (4)
Tanzania (3)
Turchia (15)
Ucraina (1)
Uganda (5)
Ungheria (31)
Vietnam (1)
Zambia (1)

Advanced search

Cerca progetti e risultati

Results 1 - 10 of 971
Results/page:
12 3 4 5 6 7 8 9 10 > >| 
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates
ID: 681032
Data di inizio: 2016-01-01, Termine: 2020-12-31
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage...
Programme: H2020-EU.3.1.
Record Number: 199828
Last updated on: 2017-06-23
Periodic Reporting for period 1 - EHVA (European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates)
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage...
Programme: H2020-EU.3.1.
Record Number: 198299
Last updated on: 2017-05-18
Personalised Risk assessment in febrile illness to Optimise Real-life Management across the European Union
ID: 668303
Data di inizio: 2016-01-01, Termine: 2020-12-31
The management of febrile patients is one of the most common and important problems facing healthcare providers. Distinction between bacterial infections and trivial viral infection on clinical grounds is unreliable, and as a result innumerable patients worldwide undergo...
Programme: H2020-EU.3.1.
Record Number: 199752
Last updated on: 2017-06-23
Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen
ID: 668353
Data di inizio: 2016-01-01, Termine: 2020-12-31
Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx...
Programme: H2020-EU.3.1.
Record Number: 199754
Last updated on: 2017-05-30
“In Vivo Click PET Imaging Agents”: Improving clinical companion diagnostics
ID: 668532
Data di inizio: 2016-01-01, Termine: 2020-12-31
Companion diagnostics are crucial for drug development and disease management with regard to patient selection, therapy planning and monitoring. Nanomedicines such as antibodies have been proven to be optimal disease-targeting agents because they generally exhibit superior...
Programme: H2020-EU.3.1.
Record Number: 199755
Last updated on: 2017-06-27
Imaging the Force of Cancer
[PROGETTO] FORCE - Imaging the Force of Cancer
ID: 668039
Data di inizio: 2016-01-01, Termine: 2019-12-31
Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges...
Programme: H2020-EU.3.1.
Record Number: 199748
Last updated on: 2017-06-16
Improving Diagnosis by Fast Field-Cycling MRI
ID: 668119
Data di inizio: 2016-01-01, Termine: 2019-12-31
Many diseases are inadequately diagnosed, or not diagnosed early enough by current imaging methods. Examples of unmet clinical needs arise in thromboembolic disease, osteoarthritis, cancer, sarcopenia, and many more areas. Our solution, Fast Field-Cycling (FFC) MRI, can...
Programme: H2020-EU.3.1.
Record Number: 199749
Last updated on: 2017-02-22
Chimeric Antigen Receptors (CARs) for Advanced Therapies
ID: 667980
Data di inizio: 2016-01-01, Termine: 2019-12-31
Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to...
Programme: H2020-EU.3.1.
Record Number: 199744
Last updated on: 2017-06-02
GALAXY: Gut-and-liver axis in alcoholic liver fibrosis
ID: 668031
Data di inizio: 2016-01-01, Termine: 2021-12-31
Alcohol overuse is an important societal challenge with annual healthcare costs of over €22 billion in Europe. Alcohol is the main cause of liver cirrhosis, which is the 5th and 7th most common cause of life years lost in respectively Eastern and Western Europe. Cirrhosis is...
Programme: H2020-EU.3.1.
Record Number: 199746
Last updated on: 2017-05-12
Intra Erythrocyte  Dexamethasone  in  the  treatment  of  Ataxia Telangiectasia
ID: 667946
Data di inizio: 2016-01-01, Termine: 2019-04-30
The main objective of the project is to provide a treatment of the neurological symptoms of patients with Ataxia Telangiectasia (AT), a rare progressively disabling and life-shortening genetic disease for which no therapy is currently available. To achieve this, a pivotal...
Programme: H2020-EU.3.1.
Record Number: 199743
Last updated on: 2017-03-01
12 3 4 5 6 7 8 9 10 > >| 
List retrieved on: 2017-07-27